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Mutations in the COL4A4 gene in thin basement membrane Hematuria is common in the community (abstract; Chad-
disease. ban et al, Nephrology 5:A107, 2000), and phase contrast
Background. Patients with thin basement membrane disease urine microscopy demonstrates that most persistently hem-(TBMD) are often from families where hematuria segregates
aturic individuals have red blood cells (RBC) that are dys-with the COL4A3 and COL4A4 genes. These genes also are
morphic in appearance reflecting their glomerular origin.affected in autosomal recessive Alport syndrome. The aim of
this study was to demonstrate COL4A4 mutations in TBMD. Studies of renal biopsies in unselected cases of persistent
Methods. Forty-eight unrelated individuals with TBMD who dysmorphic hematuria show that its most common cause
had no family members with autosomal recessive Alport syn- is thin basement membrane disease (TBMD) or benigndrome were examined for COL4A4 mutations. The diagnosis
familial hematuria [1], which is characterized by a uni-of TBMD had been confirmed by renal biopsy (43/48, 90%)
formly-thinned glomerular basement membrane (GBM).or by a family history of hematuria but without a renal biopsy
(5/48, 10%). The 47 coding exons of COL4A4 were screened As the name benign familial hematuria indicates, TBMD
for mutations with the methods of enzyme mismatch cleavage is usually inherited and the inheritance pattern is autosomal
or single stranded conformational polymorphism (SSCP) anal-
dominant [2, 3]. Thus, while the diagnosis of TBMD mayysis, and exons that demonstrated electrophoretic abnormali-
be suspected clinically, it can be confirmed by the demon-ties were sequenced.
Results. Nine variants that altered the coding sequences stration of a thinned GBM on renal biopsy or by the pres-
were identified. These were nonsense and frameshift mutations ence of additional family members with hematuria [4], since
that resulted in stop codons (N  3), and glycine (N  3) and other familial forms of glomerulonephritis are rare.
non-glycine missense variants (N  3). Four intronic variants
Alport syndrome is a less common but better understoodand three neutral polymorphisms were also detected. In total,
inherited abnormality of the GBM. Affected individualsfour variants were considered ‘pathogenic’ principally because
they resulted in stop codons or were not present in non-hema- typically have hematuria, renal failure, deafness and ocu-
turic normal subjects. Three variants were considered ‘possibly lar abnormalities, and their GBM is often lamellated.
pathogenic’ but two of these were each present in one of 46 Inheritance is usually X-linked or autosomal recessive,non-hematuric normal subjects.
when mutations occur in the COL4A5 [5] or COL4A3/Conclusions. Pathogenic COL4A4 mutations were demon-
COL4A4 genes [6–8], respectively.strated in three of the nine (33%) families in whom hematuria
segregated with the COL4A3/COL4A4 locus. Two stop codons The demonstration of a thinned GBM in heterozy-
(R1377X and 2788/91delG) and a glycine substitution (G960R) gotes from families with autosomal recessive Alport syn-
resulted in hematuria in all 16 members who were tested from drome (abstract; Netzer et al, J Am Soc Nephrol 10:A2219,these three families. The S969X mutation described here in
1999) [9, 10] first suggested that TBMD might representTBMD for the first time, as well as the R1377X mutation, also
occur in autosomal recessive Alport syndrome. a carrier state for this condition (abstract; Lambrecht et
al, J Am Soc Nephrol 7:1616A, 1996) [11, 12] or at least
be due to mutations in the same genes. Although carriers1Mark Buzza and Hayat Dagher contributed equally to this work, and
should be considered co-first authors. of X-linked Alport syndrome also can have thinned glo-
merular membranes [13], they are usually identified by
Key words: gene mutations, hematuria, heredity, S969X mutation,
a family history of renal failure or inherited deafness,R1377X mutation, dysmorphic red blood cells, benign familial hematu-
ria, familial glomerulonephritis. localized regions of GBM lamellation, and mutations in
the COL4A5 gene.Received for publication February 10, 2002
We have recently demonstrated that eight familiesand in revised form June 5, 2002
Accepted for publication October 1, 2002 from a total of 22 (36%) with biopsy-proven TBMD had
hematuria that segregated with the COL4A3/COL4A4 2003 by the International Society of Nephrology
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locus [14]. This observation confirms that TBMD is often restriction fragment length polymorphism [9, 19, 20].
caused by mutations in the genes that are affected in au- Each 10 L reaction mix contained 50 ng genomic DNA,
tosomal recessive Alport syndrome. The aim of the present 50 ng primers end-labeled with 32P-ATP (GeneWorks,
study was to determine COL4A4 mutations that caused Adelaide, South Australia) using T4 polynucleotide ki-
TBMD and to correlate these mutations with clinical nase (GeneWorks), as well as 2 mmol/L dNTP (Phar-
features. macia, Uppsala, Sweden), 1 L of 10 reaction buffer
(Gibco BRL, Life Technologies, Gaithersburg, MD,
USA), 1L of polymerase chain reaction (PCR) enhanc-METHODS
ing solution (Gibco BRL, Life Technologies), 2.5 mmol/L
Patients MgCl2 (GeneWorks) and 0.5  Taq polymerase (Gene-
Forty-eight unrelated individuals with TBMD were Works). After amplification, 5 L of formamide stop
studied. They were of Northern and Southern European, solution [95% formamide, 20 mmol/L ethylenediamine-
Middle Eastern, Chinese and Indian origins, and com- tetraacetic acid (EDTA)] were added to the reaction,
prised 11 males and 37 females with a median age of 49 incubated at 95C for ten minutes and chilled on ice. Six
years (range 7 to 71). All had 50,000 dysmorphic or L from each reaction mix were then electrophoresed
glomerular RBC/mL on phase contrast microscopy [15] in a 7% denaturing polyacrylamide gel at 80 W for two
of a midstream urine specimen on at least two occasions, to four hours at 50C. Alleles were determined by expos-
11 (11 of 45, 24%) had a maximum recorded urinary pro- ing the gel to X-ray film (AGFA) and were assigned
tein 300 g/dL and all had normal renal function (serum arbitrary numbers according to band size. Genotypes
creatinine 0.12 mmol/L). None had a clinically detect- for the Hae III polymorphism were determined after
able hearing loss, and two had normal audiometry. None amplification, restriction with Hae III (Boehringer Mann-
of the 48 knew of another family member with X-linked heim, Mannheim, Germany) at 37C for four hours, and
or autosomal recessive Alport syndrome, renal failure electrophoresis in a 2% agarose gel.
or inherited hearing loss. These individuals had been Haplotypes were constructed at the COL4A3/COL4A4
followed for a median of eight years (range 3 to 17). locus for affected and unaffected family members. In
The diagnosis of TBMD was confirmed in 43 (90%) general families were too small for formal linkage studies
with the ultrastructural demonstration of diffuse GBM and for LOD scores to be meaningful, but the probabili-
thinning on renal biopsy, and an average GBM width ties of hematuria segregating with the putative disease
250 nm calculated from 50 random measurements [16]. haplotypes by chance alone were calculated [14].
None of the biopsies had light microscopic or immuno-
fluorescent features of additional superimposed forms Mutation detection
of glomerulonephritis, and none had lamellation sugges-
For each index case, all 47 COL4A4 coding exonstive of X-linked Alport syndrome. In five cases (10%),
[10] were screened for mutations, whether or not theirno renal biopsy was performed, and the diagnosis of
families were examined and hematuria segregated withTBMD had been confirmed by a family history of hema-
the COL4A3/COL4A4 locus. Single stranded conforma-turia alone.
tional polymorphism analysis (SSCP) [21] was used forFamily studies were performed for 24 of the 48 patients
about two-thirds of the amplicons and enzyme mismatch(50%). All available family members were examined and
cleavage [22] in the remainder.the median number studied was five (range 3 to 19).
For SSCP, both forward and reverse primers for eachHematuria of 30,000 glomerular RBC/mL urine was
exon were end-labeled with 32P-ATP (GeneWorks) us-used to identify affected individuals, because hematuria
ing T4 polynucleotide kinase (GeneWorks). PCR ampli-is the most common clinical feature in TBMD; it persists
fication was performed in a 5 L reaction containingthroughout life, and does not occur at this level in normal
25 ng of each labeled primer, 1 mmol/L dNTP (Phar-subjects.
macia), 0.5 L 10 reaction buffer (Gibco BRL, LifeFamilies where hematuria segregated with the COL4A5
Technologies) 0.5 L 10 PCR enhancing solutionlocus for X-linked Alport syndrome with the DXS456,
(Gibco BRL, Life Technologies), 1.25 mmol/L MgCl2,2B20 and 2B6 markers [17, 18] had been excluded in
0.5  Taq polymerase (GeneWorks), and 20 ng of geno-preliminary studies.
mic DNA from index patients. After the reaction was
Linkage to COL4A3/COL4A4 locus complete, 20 L of SSCP loading buffer (95% form-
amide, 5 mmol/L NaOH, 0.1% bromophenol blue, 0.1%DNA from peripheral blood leukocytes or buccal brush-
xylene cyanol) were added to each tube, and the samplesings was extracted and amplified using standard tech-
heated to 95C for five minutes, and chilled on ice. Fiveniques and published conditions. Linkage to the COL4A3/
L from each sample were then loaded onto a 6% non-COL4A4 locus was examined using the CA11, D2S351
and D2S401 markers and a COL4A4 Hae III intragenic denaturing polyacrylamide gel, and electrophoresed in
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0.6  TBE at 10 W for five to eight hours at 4C. Gels on renal biopsy in at least one member, and the other
five were diagnosed on clinical features and a familywere exposed to X-ray film for one to 20 hours at	80C.
With the enzyme mismatch cleavage method, patient history of hematuria.
Nine families (47%) had hematuria that segregatedand wild-type COL4A4 exons were amplified separately
using specific primers, which for wild-type DNA had with or was consistent with segregation with the COL4A3/
COL4A4 locus (Table 1, P  0.0001 to P  0.5).been end-labeled with 32P-ATP. The amplification prod-
ucts were purified using “Freeze ’N Squeeze” spin col- Nine coding sequence variants were identified in the
48 patients with TBMD (Tables 1 and 2). These wereumns (BioRad, Herts, UK), and 50 ng of each sample
and wild-type DNA were then heated to 95C for 6.5 nonsense and frameshift mutations that resulted in stop
codons (N  3), glycine missense variants that producedminutes, 65C for 30 minutes and 25C for 20 minutes
to allow heteroduplex formation. Five L of a 10  arginine or glutamic acid substitutions (N  3) and non-
glycine missense variants (N  3). In addition four in-restriction buffer [0.5 mol/L Tris, 100 mmol/L MgCl2,
5 mmol/L dithiothreitol (DTT), bovine serum albumin tronic variants and three neutral polymorphisms were
found.(BSA) 1 mg/mL; Boehringer Mannheim] were added
and the reaction mix incubated with 250 units of T7 The three nonsense and frameshift mutations (S969X,
R1377X and 2788/91delG) resulted in premature stop co-endonuclease I in a total volume of 50 L at 37C for
20 to 25 minutes, precipitated with 100% ethanol, and dons and potentially shortened the corresponding 
4(IV)
chains by 721, 313 and 829 amino acids, respectively. Inthe precipitate resuspended in 5 L of stop solution
(95% formamide, 20 mmol/L EDTA). This was electo- reality, however, such mutations usually produce tran-
scripts that are degraded by the nonsense-mediatedphoresed in a 7% denaturing acrylamide gel (with 5.6
mol/L urea and 32% formamide) at 80 W for about one mRNA decay pathway [26]. These three variants were
all considered pathogenic. R1377X and 2788/91delG seg-hour per 100 bp of product. The gel was exposed to X-ray
regated with hematuria in the families in which theyfilm for 1 to 10 hours at 	80C. Mutations in exons were
occurred, but the family of the patient with the S969Xdemonstrated by novel banding patterns on autoradi-
mutation was not examined.ography, that reflected the different sizes of digested
There were three glycine substitutions. G960R wassample and wild-type DNA heteroduplexes wherever
present in only one of the 48 patients with TBMD andthere were mismatches.
in none of 40 non-hematuric normal subjects. It affected
Sequencing a glycine within a highly-conserved region of the collage-
nous domain gly-X-Y repeats, segregated with hematuriaAll exons that demonstrated band shifts with SSCP
in the family in which it occurred, and was consideredor where cleavage products differed from wild-type DNA
pathogenic. Both G116E and G999E were found in onlywith the enzyme mismatch cleavage method were ampli-
one and two patients, respectively, of the 48 with TBMD.fied (Big Dye terminator; Perkin-Elmer, Warrington,
However, each variant also was present in one non-UK), purified, and sequenced in both directions in an
hematuric normal subject, who knew of no other familyautomated DNA sequencer.
members with hematuria but had not had TBMD ex-Mutations were usually considered pathogenic if they
cluded by renal biopsy. Both G116E and G999E wereresulted in stop codons, or changed the amino acid se-
considered ‘possibly pathogenic,’ since mutations thatquences but were not present in racially-matched non-
result in glycine substitutions in the type IV collagenhematuric normal subjects. Other considerations were
chains are often pathogenic [10] and pathogenicity couldthe variants being located in regions of the gene that
not be excluded.were conserved in different type IV collagen isoforms
There were also three non-glycine substitutions: P482S,and in different species, and the variants segregating with
L1004P and P1132L. Both P482S and L1004P have beenhematuria within individual families.
described in heterozygous and homozygous forms in non-This project had the approval of the Human Research
hematuric normal subjects, and are considered normalEthics Committee of the Austin and Repatriation Medi-
variants [10]. P1132L was present in only one of the 48cal Centre, and all participants provided signed, informed
patients with TBMD, none of 40 non-hematuric normalconsent to the study.
subjects, and affected a conserved proline [24]. These
features suggested pathogenicity, but the mutation did
RESULTS not segregate with hematuria in the affected family,
Forty-eight patients with TBMD were studied. These where the index case’s father and son had the mutation
comprised 19 individuals from families with at least two but no hematuria. This absence of hematuria also was
members with hematuria and 29 individuals where family consistent with ‘incomplete expression,’ and for these
members were not affected (N  9) or not studied (N  reasons P1132L was considered ‘possibly pathogenic.’
Four intronic substitutions were identified. The 3 in-20). Fourteen of the 19 families had TBMD confirmed
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Table 1. Segregation of hematuria with the COL4A3/COL4A4 locus and COL4A4 sequence variants in patients with
thin basement membrane disease (TBMD) and their families
N family members N family members COL4A3/ Mutation segregated
Proband relatives tested with hematuria COL4A4 (P) Mutation with hematuria
Renal biopsy and family history (N  14)
JW 19 11 Yes (0.0001)
TW 11 9 Yes (0.0005) G960R Yes
RC 7 5 Yes (0.008)
CC 7 5 Yes (0.031)
NE 7 7 Yes (0.031)
AC 5 4 Yes (0.125) R1377X Yes
JK 4 4 Yes (0.25)
MS 4 3 Yes (0.25) 2788/91delG Yes
MC 6 4 No
NM 6 2 No
HC 4 3 No
MK 4 3 No
BS 4 4 No
JO 4 3 No
Renal biopsy and no other family member affected (N  9)
RB 6 1 No P1132L No
CH 4 1 No
MW 4 1 No
IC 3 1 No
MB 6 1 No
RBI 6 1 N/D
RY 3 1 N/D
ML 4 1 N/D
RH 3 1 N/D
Family history but no renal biopsy (N  5)
CZ 4 2 Yes (0.5) P482S Yes
MM 5 2 No
TY 9 4 No
KB 7 3 No
RB 4 3 No
Renal biopsy and no other family members studied (N  20)
S969X, G116E, G999E, L1004P, plus intronic variants
All families where hematuria had been to shown to segregate with COL4A5 were excluded from this study. Abbreviations are: N/D, not done; NS, not significant.
Table 2. COL4A4 mutations, sequence and intronic variants, and neutral polymorphisms in 48 patients
with thin basement membrane disease (TBMD)
Effect on Presence in
Sequence variant Nucleotide change coding sequence Exon Status non-hematurics Pathogenicity
Nonsense
S969X C  G at 3114 Ser→Stop at 969 32 h N/D Yes
R1377Xa C  T at 4337 Arg→Stop at 1377 44 h N/D Yes
Frameshift
2788/91delG Del of G at 2788/91 Frameshift at 861/862; 30 h N/D Yes
Stop at 868
Glycine missense
G116E G  A at 555 Gly→Glu at 116 6 h 1/46 Possibly
G960R G  A at 3086 Gly→Arg at 960 32 h 0/40 Yes
G999E G  A at 3204 Gly→Glu at 999 33 ha 2/20 1/46 Possibly
Non-glycine missense
P482Sa C  T at 1652 Pro→Ser at 482 21 h Yes No
L1004Pa T  C at 3219 Leu→Pro at 1004 33 H 1/20; h 3/20 H 12/46; h 27/46 No
P1132L C  T at 3603 Pro→Leu at 1132 36 h 0/40 Possibly
Intronic variants
107829 C  T C  T at 107829 5 splice site 14 h N/D No
130727 T  A T  A at 130727 5 splice site 18 h N/D No
2925	5 A  Ta A  T at 2925	5 3 splice site 31 h 0/40 No
4289	36 G  T G  T at 4289	36 3 splice site 43 H 3/36 No
Neutral polymorphisms
L365 L T  C at 1303 Leu→Leu at 365 18 H 7/20 H 1/1 No
V1516V A  G at 4756 Val→Val at 1516 47 H 5/20; h 12/20 H 7/45; h 20/45 No
F1644F C  T at 5140 Phe→Phe at 1644 48 h 9/32 N/D No
Abbreviations are: H, homozygous; h, heterozygous. Figures given in the Status column refer to the frequency of homozygous or heterozygous variants in patients
with TBMD.Where no figure is given, the variant was not demonstrated by SSCP in other patients with TBMD. N/D is not done.
a Variants have been described previously (see text)
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tronic variant 2925 - 5A  T was located in the splice does not segregate with the COL4A3/COL4A4 genes
because: COL4A4 mutations do not necessarily resultacceptor site of exon 31 but has been described pre-
viously in normal subjects [10]. The other 3 intronic in hematuria (20% of heterozygous carriers of COL4A4
mutations in families with autosomal recessive Alportvariant, 4289 - 36G  T, did not create cryptic branch
or splice acceptor sites, and was found in the homozygous syndrome do not have hematuria [29]); 15% of patients
with TBMD will have de novo COL4A4 mutations ifform in TBMD and in non-hematuric normal subjects.
The 5 intronic variants were considered non-pathogenic. they occur at the same rate as mutations in the COL4A5
gene in X-linked Alport syndrome [33]; and the interpre-Our study demonstrated four ‘pathogenic’ and three
‘possibly pathogenic’ COL4A4 mutations in eight of the tation of family studies is complicated by family members
without mutations who have coincidental hematuria (ab-48 unrelated patients with TBMD. The three ‘possibly
pathogenic’ mutations have not been described as nor- stract; Chadban et al, ibid).
The pathogenicity of a sequence variant ultimatelymal variants in previous surveys of COL4A4 mutations,
which further suggests their pathogenicity. This means depends on its effects on the production, structure and
function of the corresponding protein. However, thesethat our mutation detection rate was, at most, 17%, where
the maximum expected rate would be 50%. These muta- effects are often unpredictable and we have relied on
criteria for pathogenicity that have been used in previoustions accounted for three (33%) of the nine families in
whom hematuria segregated with the COL4A3/COL4A4 reports of COL4A4 and COL4A3 mutations [8, 10]. These
are, firstly, that pathogenic variants often affect regionslocus. Five of the nine coding sequence variants (56%),
and three of the four ‘pathogenic’ mutations (75%) were of genes that code for structurally or functionally impor-
tant parts of the corresponding proteins, and that arefound in exons 30 to 33.
Mutations also were examined for any correlation with thus highly conserved in different type IV collagen iso-
forms and in different species. Secondly, the substitutionexpression of hematuria and proteinuria. Mutations that
produced stop codons (R1377X and 2788/91delG) or a of glycine with larger and more highly-charged residues
in type IV collagen chains is likely to result in pathogenicglycine substitution (G960R) resulted in hematuria in
mutations because the precise collagen heterotrimer willall 16 members of three different families. The R1377X
be disrupted. Few non-pathogenic glycine substitutionsmutation was associated with proteinuria, but S969X,
have been reported in the COL genes to date [10], andwhich also produced a stop codon, and G960R, G116E
we were reluctant to describe G116E and G999E as ‘non-and P1132L were not associated. Urinary protein levels
pathogenic’ simply because each occurred in a singlewere not available for patients with the other mutations.
non-hematuric normal subject who did not have TBMD
excluded on biopsy. Nevertheless, non-pathogenic gly-
DISCUSSION cine substitutions may be more common than previously
This report describes COL4A4 mutations in TBMD thought. Thirdly, pathogenic mutations are likely to re-
and correlates them with clinical features in patients sult in hematuria in all family members with the muta-
where there was no family history of autosomal recessive tions, although the absence of hematuria in members of
Alport syndrome. Our laboratory has already reported the family with the P1132L mutation and in similar cases
the R1377X mutation in COL4A4 [25], and other COL4A4 could be explained by ‘incomplete expression.’ Further-
mutations have also been described [26–28]. more, non-pathogenic variants also may segregate with
Thin basement membrane disease was suspected in all the COL4A3/COL4A4 locus as happened with the
our patients when there was persistent dysmorphic hema- P482S variant in CZ’s family. Finally, pathogenic muta-
turia, but no family members with Alport syndrome, renal tions should not occur in 50 non-hematuric normal sub-
failure or inherited deafness. TBMD was confirmed by jects, whereas polymorphisms, by definition, do. We ex-
renal biopsy in 90% of cases and by a family history of amined DNA from up to 46 normal subjects as well as
hematuria in the others. The most common differential the 48 patients with TBMD who should have had non-
diagnosis of persistent dysmorphic hematuria is IgA glo- pathogenic variants as often as the normal subjects. How-
merulonephritis, which is rarely inherited and is associ- ever, we were unable to exclude TBMD with incomplete
ated with a GBM of normal width. Individuals with expression of hematuria in these normal subjects because
X-linked Alport syndrome had been excluded by their none had had a renal biopsy. Other groups studying
distinctive clinical features, family history, and ultra- TBMD face similar problems in their interpretation of
structural and linkage studies. COL4A4 and COL4A3 mutations until we understand
All index cases with TBMD were examined for COL4A4 more completely the effects of these mutations on type
mutations regardless of whether their families were tested IV collagen chain production.
and hematuria segregated with the COL4A3/COL4A4 What we know of the effects of mutations in the COL
locus. Patients with TBMD may still have COL4A4 (or genes has come largely from animal models of X-linked
and autosomal recessive Alport syndrome. MutationsCOL4A3) mutations when hematuria in their families
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may result in reduced transcription of the type IV colla- mutations in TBMD [27, 28] and in autosomal recessive
Alport syndrome [10] have not confirmed a mutationalgen genes or accelerated degradation of the correspond-
ing mRNA or proteins. The mechanism is uncertain, ‘hotspot.’
The technical difficulties in demonstrating and inter-however, with reduced type IV collagen mRNA levels
occurring in Samoyeds with X-linked Alport syndrome preting COL mutations mean that mutation detection is
currently unhelpful in the routine diagnosis of TBMD.and normal levels demonstrated in the human equivalent
and in transgenic mice with autosomal recessive disease The demonstration of persistent dysmorphic hematuria,
the presence of another affected family member, and the[31–33]. Type IV collagen isoforms in the GBM are re-
duced in TBMD but mRNA expression has not been absence of a family history of X-linked Alport syndrome,
inherited renal failure or deafness all suggest the diagno-studied [34].
The overall detection rate of COL4A4 mutations in sis of TBMD. These clinical criteria may not, however,
exclude X-linked Alport syndrome where there is a deour patients with TBMD was low (17%), but increased
when only the families with hematuria that segregated novo COL4A5 mutation in a female, where the family
comprises only females and young boys, and where theat the COL4A3/COL4A4 locus were considered (33%).
The low mutation yield can be attributed to the limita- clinical features are atypical, for example, hearing is nor-
mal and renal failure occurs in later life.tions of our screening methods and to mutations in
COL4A3 and possibly other genes. The enzyme cleavage
mismatch method demonstrates nearly 95% mutations, ACKNOWLEDGMENTS
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